#1 Clinical Trials Search in Europe

Study on Breast Cancer Treatment with Carboplatin for Patients in Neoadjuvant and Metastatic Stages

1 1 1 1

What is this study about?

This clinical trial focuses on improving treatment for breast cancer, specifically in cases where the cancer is either in an early stage and being treated before surgery (neoadjuvant) or has spread to other parts of the body (metastatic). The study will use a medication called Carboplatin, which is given as a solution through an intravenous infusion. This means the medicine is delivered directly into the bloodstream through a vein. The purpose of the study is to understand how the genetic makeup of the cancer changes over time and how these changes can help in selecting the best treatment options.

Participants in the study will have samples of their tumors taken at different times: before starting treatment, during treatment if possible, and after the treatment period. These samples will be analyzed to look at the DNA of the cancer cells, which includes studying the entire genetic material of the cells. This analysis will help researchers understand the genetic characteristics of the tumors and how they change with treatment. The study will also look at other factors, such as changes in the levels of certain proteins and metabolites, which are small molecules involved in metabolism, in the body over time.

Additionally, the study will examine how the treatment affects circulating tumor DNA and cells in the blood, which can provide information about how the cancer is responding to the treatment. Researchers will also assess the levels of fatigue experienced by participants, as well as factors that might predict long-term fatigue. The study aims to provide insights that could lead to more personalized and effective treatment strategies for breast cancer patients in the future.

1 joining the study

Upon joining the study, eligibility is confirmed based on specific criteria such as the type of breast cancer, tumor size, and overall health status.

The study focuses on individuals with HER2-negative breast adenocarcinoma, ensuring adequate blood, liver, and kidney function.

2 initial assessment

An initial assessment involves collecting tumor samples for DNA analysis. This helps in understanding the genetic characteristics of the tumor.

The analysis includes whole genome sequencing to evaluate the tumor’s genomic state.

3 treatment administration

The treatment involves the administration of carboplatin, a chemotherapy drug, through an intravenous infusion.

The dosage is 10 mg/mL, and the frequency and duration of administration are determined by the study protocol.

4 ongoing monitoring

Throughout the treatment period, regular monitoring of the tumor’s response is conducted.

This includes further DNA analyses to observe any changes in the tumor’s genetic makeup.

5 post-treatment evaluation

After the treatment period, additional tumor samples are collected to assess the genomic changes.

The study aims to understand the overall change in mRNA and protein expression, as well as metabolite distribution.

6 final analysis

The final analysis includes evaluating the genomic tumor architecture and tumor cell heterogeneity.

The study also examines treatment-induced changes in circulating tumor DNA and cells in the blood.

Who Can Join the Study?

  • The patient must have breast cancer that is confirmed by a test called histology or cytology. This means the cancer is checked under a microscope.
  • The cancer must be HER2-negative. HER2 is a protein that can affect the growth of cancer cells.
  • The patient can be a man or a woman.
  • The cancer must be measurable by a scan and larger than 20 mm.
  • The Ki67 labeling index must be 20% or higher for certain tumor sizes. This index measures how fast cancer cells are growing.
  • The patient must have a WHO performance status of 2 or less. This is a scale that measures how well a person can perform daily activities.
  • The patient must have adequate blood function, meaning:
    • Enough neutrophils, a type of white blood cell, with a count of at least 1.0 x 109/L.
    • Enough platelets, which help with blood clotting, with a count of at least 100 x 109/L.
    • Enough hemoglobin, which carries oxygen in the blood, with a level of at least 10 g/dL. Blood transfusions can be used to reach this level if needed.
  • The patient must have adequate liver function, meaning:
    • Total bilirubin must be less than 1.5 times the upper limit of normal. Bilirubin is a substance made by the liver.
    • AST and ALT, which are liver enzymes, must be less than 2.5 times the upper limit of normal for one group of patients, and less than 5 times for another group.
  • The patient must have adequate kidney function, meaning:
    • Serum creatinine must be 1.25 times the upper limit of normal or less. Creatinine is a waste product filtered by the kidneys.
    • If measured, creatinine clearance should be within normal reference values. This measures how well the kidneys are working.
  • The patient must be within certain age ranges, which are typically adults.

Who Cannot Join the Study?

  • Patients who are not diagnosed with breast cancer cannot participate.
  • Individuals who are not within the specified age range for the study cannot participate. The age range is not specified here, but it is important for eligibility.
  • Both males and females can participate, so gender is not a reason for exclusion.
  • Individuals who are part of a vulnerable population, such as those who cannot give consent or are at higher risk, are not automatically excluded unless specified.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

Site Name City Country Status
Oslo Universitetssykehus HF Oslo Norway

Other Sites

No sites found in this category

Want to learn more about this study or check if you can participate? Contact us.

Trial status

Country Status Recruitment Start
Norway Norway
Recruiting
07.05.2014

Trial locations

Investigated drugs:

I-BCT-1 is an investigational treatment being studied for its potential to improve breast cancer therapy. It is being tested in both the neoadjuvant (before surgery) and metastatic (advanced cancer) settings. The trial aims to understand how this treatment can be optimally selected based on the biological characteristics of the tumor. The study involves analyzing tumor samples to observe genetic changes over time, which may help in tailoring the treatment to individual patients’ needs.

Investigated diseases:

Breast Cancer – Breast cancer is a disease where cells in the breast grow uncontrollably, forming a tumor that can often be felt as a lump or seen on an X-ray. It typically begins in the cells of the milk-producing ducts or the glandular tissue called lobules. As the cancer progresses, it can invade nearby tissues and spread to other parts of the body through the lymphatic system or bloodstream. The progression of breast cancer can vary greatly, with some tumors growing slowly and others developing more rapidly. Changes in the tumor’s genetic makeup can occur over time, influencing its behavior and response to treatment. Understanding these genetic changes is crucial for developing targeted therapies and managing the disease effectively.

Trial ID:
2024-515087-31-00
Trial Phase:
Human Pharmacology (Phase I) – Other

Other Trials to Consider

  • A study to test the safety and effectiveness of ONA-255 in patients with advanced cancer including breast cancer and gastric cancer

    Recruiting

    2 1 1
    Investigated diseases:
    Spain

  • A Study Comparing GDC-4198 Alone and with Giredestrant versus Abemaciclib with Giredestrant for Advanced Breast Cancer After Previous CDK4/6 Treatment

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    France Germany Italy Spain